Panelists at the 2025 Cell & Gene Meeting on the Mesa laid out the challenges and opportunities facing the industry as it looks to produce these therapies at scale.
The CDMO introduced new cytokine and media systems designed to improve scalability, consistency and efficiency in viral vector and cell therapy production.
The Boston-based biotech’s system reportedly streamlines large-scale viral vector production and reduces costs and variability in gene therapy manufacturing.
